If you take fisetin for "cellular cleanup," a new paper from the University of Minnesota has an awkward message: the researchers say fisetin's efficacy is suboptimal and its bioavailability is poor. So they built two upgraded cousins. The catch is that you can't buy them, they've only been tested in cells and mice, and the people who made them stand to profit.
What the researchers actually did
The study, published in Aging Cell, comes from a team including Laura Niedernhofer and Paul Robbins at the Masonic Institute on the Biology of Aging and Metabolism. They started with fisetin, a natural flavonoid that has already moved into clinical trials as a senolytic. Senolytics are agents meant to selectively eliminate senescent cells, the "zombie" cells that stop dividing but linger and are linked to aging and many age-related diseases.
The authors' premise is blunt. Fisetin is promising, but they describe it as limited by suboptimal efficacy and poor bioavailability. Using what they call an integrative phenotypic drug discovery approach, they developed two fisetin-derived flavonoid compounds, SR29384 and SR31133.
Phenotypic drug discovery means screening compounds for a desired effect in cells or organisms, here the clearance of senescent cells, rather than designing a drug against one pre-chosen target.
The headline findings
According to the abstract, the new compounds:
- Showed enhanced senolytic activity compared with the fisetin starting point
- Targeted a broad range of senescent cell types
- Reduced tissue senescence in mouse models of aging
- Improved healthspan-associated parameters in those mice
The abstract does not give effect sizes, so this article doesn't either. The authors' own summary is that the compounds have "high translational potential," which is a statement of hope, not a demonstrated result in people.
How might they work?
The team combined transcriptomics, machine learning, network pharmacology and molecular docking to guess at the mechanism. Their analysis suggests the compounds may act on:
- PARP1
- CDK2
- Possibly BCL-xL
The result, they propose, is selective induction of apoptosis (programmed cell death) in senescent cells. Note the hedged language: "may target" and "possibly." Much of this evidence comes from computational and network-based methods, which generate hypotheses rather than settle them.
BCL-xL is a protein family member often discussed in senolytic research because senescent cells tend to rely on pro-survival pathways to stay alive. Blocking those pathways can tip them into dying. The paper's cautious wording on BCL-xL suggests that part is still unconfirmed.
Read the fine print: mice, patents and conflicts
This is where the clickbait question "is fisetin useless?" needs a sober answer.
It's preclinical. The work is in cells and mouse models. There are no human data on SR29384 or SR31133 in this paper.
You can't buy these compounds. They are experimental research molecules, not supplements. Anything online claiming to sell them should be treated with serious suspicion.
There's a financial angle. The conflict-of-interest statement says Niedernhofer and Robbins are cofounders of Itasca Therapeutics, a company developing senotherapeutics for aging and age-related diseases. Several authors and the University of Minnesota have also filed a provisional patent on flavonoid analogs, including these two compounds, as a strategy to treat age-related diseases.
That doesn't invalidate the science. Academic-to-biotech pipelines are normal, and the disclosure is exactly what transparency looks like. But it does mean the study should be confirmed independently, and readers should weigh the enthusiastic framing accordingly.
What this means if you take fisetin now
The paper doesn't say fisetin is worthless. It says fisetin progressed to clinical trials but has limits in efficacy and bioavailability, and that motivated the new designs. That's a reasonable reason to temper expectations, not necessarily to panic.
Forms people commonly buy: Fisetin supplements are typically sold as capsules, and some products use liposomal or other enhanced-delivery formulations aimed at the absorption problem. This paper did not test any commercial product, and it gives no guidance on dosing for humans. Doses and schedules on store shelves vary widely, and the study offers no basis for choosing among them.
Who might reasonably follow this research: People interested in senolytics who want to understand where the field is heading, and who are comfortable that current supplement use rests on limited human evidence.
Who should be cautious or skip it:
- Anyone who is pregnant or breastfeeding
- People on prescription medications, especially blood thinners, or with serious medical conditions, who should talk to a clinician before taking any senolytic-style supplement
- Anyone hoping that taking more fisetin will mimic what these new compounds did in mice. The study gives no reason to believe that
- Anyone tempted to buy "next-generation fisetin" from gray-market sellers
The bigger picture
The study reflects a broader pattern in longevity science: a natural compound shows biological promise, then chemists try to improve on it. Whether SR29384 and SR31133 survive toxicology, pharmacokinetics and human trials is unknown. Many compounds that look strong in mice fail later.
What to watch for next: independent replication, published safety data, and any move toward human trials by Itasca Therapeutics or others. Until then, treat this as a promising lead in the senolytic field, not a reason to change your supplement stack.
This article is for informational purposes and is not medical advice.